Home » Newsletters » BioWorld Science

BioWorld Science

July 24, 2017

View Archived Issues

EMA's CHMP grants positive opinion for dupixent for the treatment of atopic dermatitis

FDA grants clearance to first neonatal magnetic resonance imaging device

DNA vaccines targeting alpha-synuclein show promise for the treatment of dementia

EMA committee backs approval of Janssen's Symtuza

FDA gives orphan drug exclusivity to CSL Behring's Haegarda

FDA approves new self-injectable formulation of Benlysta

FDA awards fast track designation to Valneva's Lyme disease vaccine candidate VLA-15

AbbVie's Humira receives positive opinion from EMA for uveitis

Phase I PK/PD data presented for Eisai's PDE9A inhibitor E-2027

Lutathera receives positive opinion from EMA for GEP-NETs

GSK and Innoviva seek E.U. approval of extended use of Relvar Ellipta

Chugai files for Japanese approval of emicizumab in hemophilia A

ORIC Pharmaceuticals presents glucocorticoid receptor antagonists

Council of Scientific and Industrial Research divulges compounds for vitiligo treatment

CHMP supports approval of Novartis' Rydapt in E.U.

Chiesi Farmaceutici discloses MAPK14 inhibitors

Xermelo obtains positive opinion from EMA committee

NeuroDerm to be acquired by Mitsubishi Tanabe Pharma

Cancer Research Technology discovers TTK inhibitors

CHMP grants positive opinion for Keytruda in urothelial carcinoma

Sichuan Haisco Pharmaceutical discovers compounds for asthma treatment

CHMP recommends approval of avelumab for metastatic Merkel cell carcinoma

CHMP issues negative opinion on Vanda Pharmaceuticals' Fanaptum

EMA committee issues new Day 180 list of outstanding issues for abaloparatide

Tissue Regenix to acquire CellRight Technologies

Identified a rare variant in ADAM17 gene tied to familial Alzheimer's disease

EMA's CHMP recommends approval of Gazyvaro for previously untreated advanced follicular lymphoma

EMA committee recommends approvals for Tecentriq in NSCLC and metastatic urothelial carcinoma

RoActemra recommended for approval in E.U. for giant cell arteritis